Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation
Authors:
- 14 March 2020
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 28 (11) , 5491-5499
Abstract
Purpose The contribution of acute graft-versus-host disease (GVHD) to healthcare resource utilization (HCRU) and costs following allogeneic hematopoietic cell transplantation (HCT) has not been extensively investigated. The objective of this study was to estimate both inpatient and outpatient HCRU and costs associated with acute GVHD during the 100-day and 1-year periods after allogeneic HCT in the USA. Methods A retrospective analysis of administrative claims from the Optum® Research Database of patients aged ≥ 12 years who received HCT between 2010 and 2016 was conducted. Costs and HCRU among patients with acute GVHD and no GVHD were compared during the 100-day (acute GVHD, n = 723; no GVHD, n = 385) and 360-day (acute GVHD, n = 445; no GVHD, n = 227) periods after HCT. Results Patients with acute GVHD had significantly more (P < 0.001) mean office visits (47 vs 32), hospital outpatient visits (71 vs 35), and inpatient stays (2.8 vs 1.1) than patients with no GVHD during 360 days post-HCT; similar findings were observed over the 100-day period. Mean total all-cause costs were significantly higher (P < 0.001) for patients with acute GVHD versus no GVHD during both post-HCT periods (100-day, $316,458 vs $215,229; 360-day, $466,720 vs $263,568). Additional factors associated with increased 360-day costs included young age (12–17 years; P < 0.001) and peripheral blood as graft source (P = 0.03). Conclusion Acute GVHD was associated with significant HCRU and costs in the first 100 days of transplant, increasing over the first year post-HCT. Inpatient care was the primary driver, but outpatient care and related costs were also increased.Keywords
Funding Information
- Incyte Corporation (N/A)
This publication has 11 references indexed in Scilit:
- Mortality, length of stay and costs associated with acute graft-versus-host disease during hospitalization for allogeneic hematopoietic stem cell transplantationCurrent Medical Research and Opinion, 2018
- Acute Graft-versus-Host Disease — Biologic Process, Prevention, and TherapyNew England Journal of Medicine, 2017
- Improved survival after acute graft- versus -host disease diagnosis in the modern eraHaematologica, 2017
- Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling DonorsTransplantation and Cellular Therapy, 2016
- Role of Hematopoietic Stem Cell Transplantation in Patients with Myeloproliferative DiseaseHematology/Oncology Clinics of North America, 2014
- High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHDClinical Transplantation, 2012
- Risk factors for acute GVHD and survival after hematopoietic cell transplantationBlood, 2012
- The EBMT activity survey 2009: trends over the past 5 yearsBone Marrow Transplantation, 2011
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Graft-versus-host diseaseThe Lancet, 2009